Table 3.

Multivariable analysis of OS and time to CNS metastasis in patients with BRAFV600 mutations

OSTime to CNS Metastasis
MeasureHR (95% CI)PHR (95% CI)P
Stage III status (IIIC vs. IIIB)2 (0.9–4.2)0.091.4 (0.5–3.7)0.503
PTEN (absent vs. not absent)2.7 (1.3–5.5)0.0084.2 (1.5–12.0)0.008
BRAF inhibitor use (no vs. yes)3 (0.4–23.3)0.2853 (0.4–23.8)0.299
Ipilimumab use (no vs. yes)1 (0.3–3.0)0.9761.2 (0.4–4.2)0.741
Age1 (1.0–1.0)0.5491 (1.0–1.0)0.98
Gender (male vs. female)1.5 (0.7–3.8)0.2932.1 (0.7–6.2)0.179